- Poster presentation
- Open Access
Our experience in second line Anti Retroviral Therapy (ART) At State Aids Clinical Expert Panel (SACEP) Clinic, Centre of Excellence (CoE), Art Centre, B. J. Medical College, Civil Hospital, Ahmedabad
© Mankad et al; licensee BioMed Central Ltd. 2010
- Published: 11 May 2010
- Infectious Disease
- Cancer Research
- Treatment Failure
- Line Treatment
- State AIDS
To share our experience in second line Anti Retroviral Therapy (ART) at State AIDS Clinical Expert Panel (SACEP) Clinic, Centre of Excellence (CoE), ART Centre, B. J. Medical College, Civil Hospital, Ahmedabad, Gujarat, India.
First line treatment failure Patients (as per Indian National ART Guidelines) were referred to SACEP Clinic for further evaluation and if eligible as per Indian National 2nd Line ART Guidelines; enrolled and followed up for initiation of 2nd Line ART at our institute.
Total Patients referred to SACEP
Patients Eligible and referred for Plasma Viral Load (PVL) (n = 127)
Patients recommended 2nd Line ART after PVL (n = 122)
Patients initiated Free 2nd Line ART (n = 75)
Patients under follow up TB Treatment/Counseling to initiate 2nd Line ART
Adherence Counseling for 2nd Line ART Patients (n = 69)
Undetectable PVL (<400 copies/ml) after 6 months of 2nd Line ART (n = 28)
Therapeutic Success according to Undetectable PVL (24/28)
No. of Death after initiation of 2nd Line ART (n = 69)
Cause of Death
n = 8
Opportunistic Infections (OIs)
Switching to 2nd Line ART based on Immunological Failure, Clinical Failure is not recommended; as out of 122 PLHAs analyzed only 75 PLHAs have Virological Failure. Adherence Counseling for 2nd Line ART helps quite in reduction of PVL. Deaths analysis shows that late switch to 2nd Line ART at CD4 < 100 cells/mm3 may not result in desired therapeutic goals.
This article is published under license to BioMed Central Ltd.